| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 831 | 3.028 | 4.682 | 12.173 | 31.166 | 40.380 | 54.626 | 261.540 | 851.819 |
| Total Income - EUR | - | 831 | 3.028 | 4.682 | 12.173 | 31.166 | 40.380 | 54.641 | 264.198 | 859.193 |
| Total Expenses - EUR | - | 0 | 313 | 680 | 672 | 2.191 | 12.844 | 19.716 | 364.385 | 746.194 |
| Gross Profit/Loss - EUR | - | 831 | 2.715 | 4.002 | 11.501 | 28.976 | 27.536 | 34.924 | -100.187 | 113.000 |
| Net Profit/Loss - EUR | - | 806 | 2.625 | 3.862 | 11.136 | 28.107 | 26.349 | 33.641 | -102.829 | 89.645 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 12 |
Check the financial reports for the company - Evocliniq Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 23.832 | 19.624 | 141.004 | 154.780 |
| Current Assets | - | 876 | 3.642 | 7.324 | 13.863 | 31.449 | 23.686 | 59.042 | 28.951 | 142.857 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.427 |
| Receivables | - | 0 | 0 | 0 | 0 | 0 | 0 | 1.570 | 17.384 | 120.556 |
| Cash | - | 876 | 3.642 | 7.324 | 13.863 | 31.449 | 23.686 | 57.473 | 11.567 | 20.874 |
| Shareholders Funds | - | 851 | 3.461 | 7.259 | 13.618 | 30.812 | 26.397 | 33.690 | -69.241 | 20.731 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 25 | 181 | 64 | 245 | 637 | 21.120 | 44.977 | 246.584 | 283.266 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8623 - 8623" | |||||||||
| CAEN Financial Year |
8623
|
|||||||||
Comments - Evocliniq Srl